Effects of lentivirus-mediated endostatin on endothelial progenitor cells
Metrics: PDF 1132 views | HTML 1423 views | ?
Jing Ai1,*, Jun-Hui Sun2,*, Jian Ma1 and Ke Yao1
1Eye Center, 2nd Affiliated Hospital of School of Medicine, Zhejiang University, Hangzhou 310009, China
2Key Laboratory of Combined Multi-Organ Transplantation, Ministry of Public Health, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China
*These authors have contributed equally to this work
Ke Yao, email: firstname.lastname@example.org
Keywords: endostatin; endothelial progenitor cells; lentiviral vector; gene transfer; cell viability
Received: July 18, 2017 Accepted: September 20, 2017 Published: October 10, 2017
Endothelial progenitor cells (EPCs) are candidates for gene therapies against retinal neovascularization (NV). The aim of present study was to investigate the effects of endostatin transfection on EPC function. In the present study, the EPCs were infected with lentivirus overexpressing endostatin. The transfection effects of endostatin overexpression on the proliferation, migratory, differentiation, apoptosis and the cell cycle of this cell line were determined. The real-time quantitative polymerase chain reaction (RT-qPCR) and western blot assays showed high expression levels of endostatin. A cell counting kit-8 assay showed that endostatin overexpression inhibited EPC proliferation. The transwell assay indicated that endostatin overexpression could suppress EPC migration. Furthermore, endostatin overexpression enhanced apoptosis (as showed by AnnexinV-FITC/propidiumiodide staining analysis), induced differentiation and blocked the cell cycle. As compared with negative control group, EPC viability significantly decreased in gene transfection group. In conclusion, present study determined the feasibility of lentivirus-mediated endostatin gene transfer, and indirectly proved the effect of endostatin secretion on EPCs. Also our study provided a new opportunity for the potential application of gene therapy in retinal NV.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.